AGIO up +9.20% percent Today $AGIO High is at 93.00 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 19, 2014 at 10:31 AM

AGIO up +9.20% percent Today $AGIO High is at 93.00 and the Low 83.68 with current volume of 1,516,641.

Recent News posted below.

Agios Pharmaceuticals Inc AGIO other info.
http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/

AGIO Agios Pharmaceuticals Inc Recent Headline News

Stock Futures Take A Data Dive; Tesla Falls On Outlook Change
at Investor's Business Daily - 1 hr 19 mins ago
Stock futures fell out of flat trade to moderate losses ahead of Wednesday's open after a mixed read on October homebuilding activity. Dow futures slumped 18.8 points below fair market value. Nasdaq 100 futures traded down 6.3 points. S&P 500 futures...
SPLS: 13.98 (+1.22), LEJU: 12.45 (-1.71), TSLA: 248.10 (-9.60), FCAU: 12.18 (-0.63), LITB: 7.75 (+0.11), TTM: 46.46 (-0.70), DL: 17.75 (+2.78), VA: 36.84 (-0.21), TGT: 71.07 (+3.56), GM: 32.10 (-0.17), AGIO: 91.55 (+7.74), LOW: 61.76 (+3.23), HMC: 31.03 (-0.62), EJ: 8.66 (-0.87), PETM: 76.40 (+2.78)

Agios leukemia drug candidate shows clinical activity in Phase 1 trial
Seeking Alpha - at Seeking Alpha - 1 hr 29 mins ago

AGIO: 91.55 (+7.74)

Agios Cancer 'Metabolism' Drug Clears Bone Marrow of Leukemic Cells
at The Street - Tue Nov 18, 5:02PM CST
The experimental drug from Agios, designed to attack the "metabolism" of cancer cells, has demonstrated early but strong clinical responses in a study involving patients with advanced leukemia.
AGIO: 91.55 (+7.74), CELG: 106.02 (-0.76)

Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity of AG-120 as a Single Agent in Advanced Acute Myeloid Leukemia (AML)
GlobeNewswire - Tue Nov 18, 5:01PM CST
-Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML -
AGIO: 91.55 (+7.74)

Jim Cramer Says to Buy Six Flags, Avoid SeaWorld Entertainment
at The Street - Wed Nov 12, 1:20PM CST
TheStreet's Jim Cramer says investors shouldn't be tricked by SeaWorld's attractive dividend yield. Instead, stick with Six Flags Entertainment.
SEAS: 17.20 (+0.14), SIX: 40.53 (-0.27), AGIO: 91.55 (+7.74)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 84.37 (-1.19), OREX: 5.54 (-0.08), PCMI: 8.86 (+0.07), CYAN: 7.69 (-0.15), ACHN: 13.10 (-0.21), TGTX: 14.49 (-0.28), AGIO: 91.70 (+7.89), LIOX: 5.05 (-0.09), SAJA: 5.97 (-0.14), PLNR: 7.23 (-0.16)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 170.72 (-0.66), SLXP: 104.96 (-0.43), ICPT: 157.87 (-4.63), IBB: 293.56 (-1.69), AGIO: 91.70 (+7.89)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST

AGIO: 91.70 (+7.89)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.63 (+0.06), ANET: 76.88 (+0.08), TKMR: 16.11 (-0.26), ORBC: 6.21 (-0.13), MDRX: 12.05 (-0.15), RMTI: 9.99 (-0.29), CTIC: 2.22 (-0.06), SHLD: 35.65 (-0.26), UBNT: 29.30 (-0.29), RIG: 25.29 (-0.56), KGC: 2.85 (-0.11), APT: 2.84 (+0.11), ANF: 28.81 (-0.13), MITK: 3.89 (-0.07), ZNGA: 2.68 (-0.03), CNET: 1.83 (-0.03), KING: 16.07 (-0.03), NETE: 1.35 (unch), SLXP: 104.96 (-0.43), RPRX: 9.07 (-0.12), NADL: 3.71 (-0.26), PGNX: 6.41 (-0.13), AVNR: 13.90 (+0.20), FSLR: 49.01 (-0.45), DVA: 74.97 (-0.26), NDLS: 22.55 (-0.10), ICPT: 157.87 (-4.63), AGIO: 91.55 (+7.74), PLNR: 7.23 (-0.16)

Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST

AGIO: 91.60 (+7.79)

Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 91.60 (+7.79)

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 91.60 (+7.79)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST

BAM: 49.66 (-0.22), ERF: 15.01 (-0.14), LXP: 10.96 (-0.01), PGEM: 12.29 (-0.14), CCOI: 34.99 (-0.16), TTI: 7.99 (-0.17), SJI: 56.40 (-0.15), NXST: 47.08 (-0.32), VSAT: 65.70 (+0.16), MT: 12.28 (-0.17), LXU: 33.33 (-0.40), HUM: 138.11 (-1.18), PGNX: 6.41 (-0.13), MHR: 4.55 (-0.07), CTB: 32.52 (unch), IDRA: 2.54 (+0.06), ISIS: 50.00 (+0.29), BPL: 81.59 (+0.19), SSP: 19.61 (-0.03), AGIO: 91.60 (+7.79), EBIX: 16.10 (-0.13)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 84.79 (-4.01), RNA: 11.45 (-0.05), AGIO: 91.72 (+7.91), CELG: 106.03 (-0.75)

Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 91.72 (+7.91)

Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 114.63 (-0.75), LNKD: 217.10 (-3.97), HAL: 48.15 (-0.39), AGIO: 91.72 (+7.91), IMPV: 41.32 (-1.21)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 101.71 (-2.00), CLVS: 50.90 (-2.88), ARWR: 5.95 (unch), ACHN: 13.11 (-0.20), MRK: 59.19 (-0.70), RTRX: 8.90 (-0.13), RGLS: 17.32 (-0.80), EPZM: 23.07 (-0.36), AGIO: 91.72 (+7.91), RMTI: 9.99 (-0.29), ARNA: 4.21 (-0.10), KERX: 15.48 (-0.06)

Cramer's Lightning Round - Isis Pharmaceuticals Has The Best Pipeline (10/28/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Oct 29, 5:59AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday October 2 8. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "Isis got slammed, and (the selloff) was overdone. It has the best pipeline...
GS: 189.02 (-0.62), RICE: 25.65 (+0.15), ISIS: 50.00 (+0.29), CYBR: 42.09 (-0.58), GNC: 43.05 (+0.16), HAL: 48.15 (-0.39), AGIO: 91.72 (+7.91), FTNT: 26.55 (-0.40)

'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 46.24 (-0.17), RICE: 25.65 (+0.15), GS: 189.02 (-0.62), FEYE: 31.30 (-0.57), ISIS: 50.00 (+0.29), CYBR: 42.09 (-0.58), GNC: 43.05 (+0.16), HAL: 48.15 (-0.39), EOG: 97.66 (-0.01), AGIO: 91.72 (+7.91), FTNT: 26.55 (-0.40)

Agios Pharmaceuticals Inc. (AGIO) Stock Research Links

AGIO Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. David Lifschutz Honored for Psychiatry Innovation

Recognizing a Legacy in Mental Wellness Under the glare of recognition's spotlight, Dr. David H. Lifschutz steps into an exclusive circle of elite professionals. He's been acknowledged as a Pinnacle Lifetime Member by The Inner Circle for his remarkable contributions to psychiatry and mental health care. This ain't just any pat on the back. It's a badge of honor stitched...

illycaffè's B Corp™ Recertification Reflects Bold Commitment

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Starr Conspiracy Unveils AI Tool for B2B Tech Firms

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

Lincoln Educational Services Faces Securities Fraud Suit

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

NSF Backs New Space Projects: Cooling & Drug Delivery

You know, every time we think we're at the edge of current science, space reminds us how little we actually know. From the International Space Station up there in low Earth orbit, fresh experiments are kicking off to change what we understand about electronics cooling and drug delivery. It's a classic scenario of reaching for the stars to help us out back here on Earth....

Microplastics Webinar: Navigating Complex Regulations

Buckle up, folks. The plastics debate is where regulatory battles and environmental concerns collide, and big changes are on the horizon. Let's talk about Bergeson & Campbell's latest shindig: "Plastics and Policy: Microplastics, EPR, and Other Emerging Trends"—a free-to-join webinar aiming to lift the lid on what's brewing beneath the surface of regulatory waters. The...

Brands Must Choose: Cost or Value Leadership?

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

Unicycive's Legal Turmoil: Opportunity for Investor Action

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

NORD Honors Innovators Shaping Rare Disease Treatment

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

New Podcast by Paralyzed Veterans of America Offers Unique Insights

Empowering Veterans Through Storytelling Some stories don't just rattle around in your headphones—they stick with you. The 'Voices of PVA' podcast, launched by Paralyzed Veterans of America, aims to do exactly that. It's not just a podcast; it's a platform where voices of veterans and people with spinal cord injuries like MS and ALS aren't just heard, they're amplified....